CL2020002650A1 - Enzimas quinureninasa humanas y sus usos - Google Patents

Enzimas quinureninasa humanas y sus usos

Info

Publication number
CL2020002650A1
CL2020002650A1 CL2020002650A CL2020002650A CL2020002650A1 CL 2020002650 A1 CL2020002650 A1 CL 2020002650A1 CL 2020002650 A CL2020002650 A CL 2020002650A CL 2020002650 A CL2020002650 A CL 2020002650A CL 2020002650 A1 CL2020002650 A1 CL 2020002650A1
Authority
CL
Chile
Prior art keywords
kinureninase
enzymes
human
methods
certain aspects
Prior art date
Application number
CL2020002650A
Other languages
English (en)
Inventor
George Georgiou
Everett Stone
John Blazeck
Christos Karamitros
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of CL2020002650A1 publication Critical patent/CL2020002650A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y307/00—Hydrolases acting on carbon-carbon bonds (3.7)
    • C12Y307/01—Hydrolases acting on carbon-carbon bonds (3.7) in ketonic substances (3.7.1)
    • C12Y307/01003—Kynureninase (3.7.1.3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Mycology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se describen métodos y composiciones relacionados con el uso de una proteína con actividad de quinureninasa. Por ejemplo, en determinados aspectos se puede describir una quinureninasa modificada capaz de degradar la quinurenina. Además, determinados aspectos de la invención proporcionan composiciones y métodos para el tratamiento del cáncer con agotamiento de quinurenina mediante el uso de las proteínas o los ácidos nucleicos descritos.
CL2020002650A 2018-04-16 2020-10-14 Enzimas quinureninasa humanas y sus usos CL2020002650A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862658261P 2018-04-16 2018-04-16

Publications (1)

Publication Number Publication Date
CL2020002650A1 true CL2020002650A1 (es) 2021-06-18

Family

ID=68240288

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2020002650A CL2020002650A1 (es) 2018-04-16 2020-10-14 Enzimas quinureninasa humanas y sus usos

Country Status (18)

Country Link
US (2) US11648272B2 (es)
EP (1) EP3781179A4 (es)
JP (1) JP7432851B2 (es)
KR (1) KR102862473B1 (es)
CN (1) CN112218644A (es)
AR (1) AR115051A1 (es)
AU (1) AU2019257340B2 (es)
BR (1) BR112020020772A2 (es)
CA (1) CA3096549A1 (es)
CL (1) CL2020002650A1 (es)
CO (1) CO2020013050A2 (es)
EA (1) EA202092487A1 (es)
IL (1) IL277765B1 (es)
MX (1) MX2020010932A (es)
SG (1) SG11202009559RA (es)
TW (1) TWI827593B (es)
WO (1) WO2019204269A1 (es)
ZA (1) ZA202006077B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102271498B1 (ko) 2013-08-30 2021-07-05 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 종양 치료를 위한 키누레닌 고갈 효소의 투여
EP3186371B1 (en) * 2014-08-29 2024-08-14 Board of Regents, The University of Texas System Administration of kynurenine depleting enzymes for tumor therapy
EP3423483B1 (en) 2016-03-02 2025-09-24 Board Of Regents Of the University Of Texas System Human kynureninase enzyme variants having improved pharmacological properties
CN114828863A (zh) * 2019-10-17 2022-07-29 医肯纳肿瘤学公司 聚乙二醇化犬尿氨酸酶以及其用于治疗癌症的用途
WO2024085280A1 (ko) * 2022-10-20 2024-04-25 서울대학교 산학협력단 신규한 키뉴레니나제 및 이의 용도

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030194721A1 (en) 2001-09-19 2003-10-16 Incyte Genomics, Inc. Genes expressed in treated foam cells
JP2005516605A (ja) 2002-02-01 2005-06-09 ミレニアム・ファーマシューティカルズ・インコーポレイテッド 心血管疾患を処置するための方法および組成物
CN1330774C (zh) 2002-03-01 2007-08-08 国家人类基因组南方研究中心 犬尿氨酸水解酶多态性及其用途
US7714139B2 (en) 2003-03-27 2010-05-11 Lankenau Institute For Medcial Research IDO inhibitors and methods of use
US20070207158A1 (en) 2003-06-17 2007-09-06 Harrison Roger G Conjugate for the specific targeting of anticancer agents to tumor cells or tumor vasculature and production thereof
CA2534639C (en) 2003-07-31 2013-07-30 Immunomedics, Inc. Anti-cd19 antibodies
JP2008237022A (ja) 2005-06-30 2008-10-09 Osaka Prefecture 非小細胞肺がんの予防・治療剤および診断薬
WO2008036642A2 (en) 2006-09-19 2008-03-27 Incyte Corporation N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
CA2776143A1 (en) 2009-10-01 2011-04-07 The United States Of America, As Represented By The Secretary, Departmen T Of Health And Human Services Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer
ES2602743T3 (es) 2010-09-08 2017-02-22 Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus Receptores de antígenos quiméricos con una región bisagra optimizada
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
WO2012099441A2 (ko) 2011-01-21 2012-07-26 인제대학교산학협력단 트립토판 대사효소 유전자를 발현하는 줄기세포를 함유하는 면역 반응 억제용 조성물
KR20120085209A (ko) 2011-01-21 2012-07-31 인제대학교 산학협력단 트립토판 대사효소 유전자를 발현하는 줄기세포를 함유하는 면역 반응 억제용 조성물
US9593062B2 (en) 2011-09-07 2017-03-14 Deutschland Krebsforschungszentrum Means and methods for treating and/or preventing natural AHR ligand-dependent cancer
ES2654060T3 (es) 2011-10-20 2018-02-12 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Receptores de antígenos quiméricos anti-CD22
KR102271498B1 (ko) 2013-08-30 2021-07-05 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 종양 치료를 위한 키누레닌 고갈 효소의 투여
EP3186371B1 (en) * 2014-08-29 2024-08-14 Board of Regents, The University of Texas System Administration of kynurenine depleting enzymes for tumor therapy
EP3423483B1 (en) 2016-03-02 2025-09-24 Board Of Regents Of the University Of Texas System Human kynureninase enzyme variants having improved pharmacological properties

Also Published As

Publication number Publication date
CO2020013050A2 (es) 2020-10-30
ZA202006077B (en) 2025-04-30
IL277765A (en) 2020-11-30
SG11202009559RA (en) 2020-10-29
US20190350975A1 (en) 2019-11-21
AU2019257340A1 (en) 2020-10-15
US20230405049A1 (en) 2023-12-21
JP7432851B2 (ja) 2024-02-19
BR112020020772A2 (pt) 2021-02-02
AR115051A1 (es) 2020-11-25
US11648272B2 (en) 2023-05-16
TWI827593B (zh) 2024-01-01
EP3781179A4 (en) 2022-11-09
EP3781179A1 (en) 2021-02-24
IL277765B1 (en) 2026-01-01
CN112218644A (zh) 2021-01-12
KR102862473B1 (ko) 2025-09-23
TW202011973A (zh) 2020-04-01
US12144828B2 (en) 2024-11-19
EA202092487A1 (ru) 2021-02-05
KR20200143455A (ko) 2020-12-23
AU2019257340B2 (en) 2025-07-24
JP2021521777A (ja) 2021-08-30
WO2019204269A1 (en) 2019-10-24
CA3096549A1 (en) 2019-10-24
MX2020010932A (es) 2020-11-06

Similar Documents

Publication Publication Date Title
CL2020002650A1 (es) Enzimas quinureninasa humanas y sus usos
MX2021013766A (es) Restos de separacion y metodos de uso de los mismos.
CL2020002755A1 (es) Ácidos nucleicos recombinantes que codifican una o más proteínas cosméticas para usos estéticos.
CO2019002609A2 (es) Proteínas de unión recombinantes y sus usos
DOP2018000245A (es) Proteinas de fusion gdf15 y usos de estas
MX2018005315A (es) Composiciones y metodos para el tratamiento del cancer.
CL2021000855A1 (es) Replicones basados en alfavirus para la administración de bioterapias.
PE20190563A1 (es) Genes de mini-distrofina optimizados y casetes de expresion y su uso
CL2019000732A1 (es) Tratamiento avv de la enfermedad de huntington.
MX2019010040A (es) Composiciones y métodos para el tratamiento del cáncer.
MX2021006531A (es) Composicion que contiene arn para tratamiento de enfermedades tumorales.
CL2024001715A1 (es) Anticuerpo aislado que se une a la proteína e del virus del dengue; y uso.
SV2007002813A (es) Compuestos para la modulacion de la actividad del c-fms y/o el c-kit y sus usos aplicables
MX376835B (es) Inhibidores de lisil oxidasa tipo 2 fluorinados y usos de los mismos.
BR112016004095A2 (pt) administração de enzimas de empobrecimento de quinurenina para a terapia contra tumores
MX2019000235A (es) Eliminacion de la cistina mediada por enzimas humanas.
MX2017014245A (es) Composiciones que comprenden celulas germinales mesenquimales y usos de las mismas.
MX378857B (es) Celulas huespedes modificadas y usos de las mismas.
CO2020006907A2 (es) Péptidos antimicrobianos y métodos para usarlos
WO2017151860A8 (en) Human kynureninase enzyme variants having improved pharmacological properties
BR112018003928A2 (pt) métodos para o tratamento de doenças
UY38352A (es) Inhibidores de integrina alfavbeta6
MX2017011934A (es) Formas solidas de menaquinoles.
MX2018006790A (es) Composiciones que contienen decitabina, 5azacitidina y etrahidrouridina y sus usos.
ECSP22019177A (es) Proteínas de fusión nkg2d y sus usos